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Introduction
Non-tuberculosis mycobacteria (NTM), also called 
opportunistic or atypical mycobacteria, are widespread 
as part of environmental microbiota (Griffith et al. 
2007). Most atypical mycobacteria are natural inhabit-
ants of various ecological niches, common for humans 
and animals, including natural waters, drinking water 
supply systems, and soil. As a result of their widespread 
expansion, humans are exposed to constant contact 
with these opportunistic microorganisms.
Non-tuberculosis mycobacteria are less pathogenic 
than Mycobacterium tuberculosis; however, they have 
become a cause of respiratory colonization increas-
ingly. Several species can induce a non-tuberculous 
mycobacterial lung disease (NTMLD), especially in 
patients with chronic lung diseases, such as cystic fibro-
sis (Adjemian et al. 2018; Gardner et al. 2019), chronic 
obstructive pulmonary disease (COPD) (Andrejak et al. 
2013; Hoefsloot et al. 2013; Diel et al. 2017), past tuber-
culosis (Adzic-Vukicevic et al. 2018; Bakuła et al. 2018; 
Szturmowicz et al. 2018), or chronic thromboembolic 
pulmonary hypertension (Wilińska et al. 2014).
To date, more than 190 species of atypical myco-
bacteria have been described. A steady increase in 
the number of newly identified species is observed as 
a result of the continuous development of molecular 
methods enabling the identification of mycobacteria 
(Tortoli 2014).
One of the most frequently isolated species was 
those belonging to M. avium complex (MAC). Tradi-
tionally, MAC has been thought to consist of M. avium 
and M. intracellulare. Presently, owing to the applica-
tion of molecular biology techniques, MAC includes 
eight species (M. avium, M. intracellulare, M. marseil­
laise, M. timonense, M. bouchedurhonense, M. colombi­
ense, M. vulneris, and M. chimaera) and four subspecies 
(M. avium subsp. avium, M. avium subsp. hominissium, 
M. avium subsp. silvaticum, and M. avium subsp. para­
tuberculosis) (Wallace et al. 2013).
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A b s t r a c t
Mycobacterium chimaera is the newly described species belonging to Mycobacterium avium complex (MAC), with morphology and growth 
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M. chimaera was first characterized in 2004 by 
Tortoli, who described 12 isolates of slow-growing bac-
teria, closely related to M. intracellulare, isolated from 
the respiratory tract (Tortoli et al. 2004). Subsequent iso-
lates came from Germany, the United States, and Zambia 
(Schweickert et al. 2008; Bills et al. 2009; Malama et al. 
2014). The natural reservoir of M. chimaera is unknown; 
however, Sax et al. (2015) showed that it is commonly 
detected in aquatic environments and biofilms.
The increased interest in M. chimaera has been asso - 
ciated with several cases of invasive cardiovascular infec- 
tion in patients undergoing cardiac surgery in the extra-
corporeal circulation (Archermann et al. 2013; Kohler 
et al. 2015; Sax et al. 2015). Environmental studies of 
the hospital’s water distribution system showed that 
M. chimaera was found in water samples collected from 
devices used for extracorporeal blood circulation. Due to 
the favorable conditions for growth, mycobacteria mul-
tiplied in water tanks and formed a biofilm. They were 
further dispersed in the air during the operation of the 
device. Positive cultures were obtained from the air sam-
ples only when the apparatus was in operation. Brand 
new devices were colonized with M. chimaera after 
only three months of operation, despite maintaining 
the equipment following the instruction (Sax et al. 2015).
Since 2011 several patients have been identified who 
underwent cardiac surgery and were diagnosed with 
M. chimaera infection. The time between the procedure 
and the appearance of NTMLD ranged from one to four 
years. Patients reported non-specific clinical symptoms, 
and the infection was identified in different organs, 
which made it difficult to correctly diagnose myco-
bacteriosis (ECDC 2015; Kohler et al. 2015). Pulmo-
nary infections due to M. chimaera have been reported 
sporadically (Alhanna et al. 2012; Hasan et al. 2017).
Thus, the present retrospective study aimed to ana-
lyze the frequency and clinical significance of M. chi­
maera isolation in the population of patients, who had 
previously obtained positive respiratory cultures for 
M. intracellulare or MAC.
Experimental
Materials and Methods
Respiratory strains of either M. intracellulare or 
MAC, identified from 2011 through 2020 by the Geno-
Type CM test (Hain Lifescience) in various respiratory 
wards, have been re-evaluated with GenoType NTM-
DR test (Hain Lifescience). This method identifies 
various MAC species via the DNA-STRIP method, 
analyzing the 23S rRNA gene polymorphism. The data 
concerning the number of specimens tested and the 
number of patients are presented in Fig. 1.
The strain identification process consisted of three 
stages: DNA isolation, amplification by biotin-labelled 
primers, and reverse hybridization. The last step 
involved the following: chemical denaturation of 
amplification products, hybridization of biotin-labelled 
single-stranded amplicons on the probe-covered mem-
brane, washing, addition of streptavidin conjugate/
alkaline phosphatase, and the staining reaction using 
alkaline phosphatase (Zabost et al. 2015).
Clinical data concerning age, sex, and concomitant 
diseases were collected from the doctors who took care 
of the patients after obtaining the patients’ agreement. 
According to the guidelines (Griffith et al. 2007; Daley 
et al. 2020), NTMLD was recognized in patients with 
new clinical symptoms, new radiological signs (infiltra-
Fig. 1. Results of M. chimaera identification in 200 respiratory samples.
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tions or nodular-bronchiectatic form of disease), and in 
whom M. chimaera was cultured once from bronchial 
washings or twice from separate sputum specimens.
Statistical analysis. All analyses were performed 
with R – a software environment for statistical comput-
ing and graphics (https://www.r-project.org/) (R core 
team 2016). Continuous variables (age) have been 
presented as means and standard deviations, categori-
cal ones – as absolute numbers and percentages of the 
entire population. Comparison of categorical parame-
ters between two groups has been performed with a chi-
square test. Comparison of continuous parameters has 
been performed with the t-Student test or the U Mann-
Whitney test. P < 0.05 was considered significant.
Results
200 respiratory strains of either M. intracellulare or 
MAC were re-evaluated. Among 195 strains initially 
classified as M. intracellulare, 86 (43.0%) were re-clas-
sified as M. chimaera. Among five cases initially identi-
fied as caused by a mixture of M. avium and M. intra­
cellulare, there were two mixed infections of M. avium 
and M. chimaera. No resistance to aminoglycosides and 
macrolides was found in the analyzed group of strains.
Therefore, a total of 88 out of 200 strains (44%) iso-
lated from 37 patients were re-classified as M. chimaera. 
Further analysis included 30 patients from whom the 
clinical information has been obtained. There were 
14 women and 16 men aged 26–92 years (median age 
– 60 years).
Diseases concomitant with M. chimaera infection 
were presented in Table I. The three most frequent co-
morbidities were COPD, past tuberculosis, and inter-
stitial lung diseases. In 23% of patients, two or more 
coexisting diseases have been recognized.
The patterns of most frequent respiratory co-mor-
bidities in patients with positive M. chimaera cultures 
were different in males compared to females (Table I). 
COPD, past tuberculosis, and interstitial lung diseases 
were diagnosed more often in men, cystic fibrosis and 
bronchiectasis – in women.
Criteria of NTMLD, according to ATS/IDSA 
(Griffith et al. 2007), as well as to the recent interna-
tional guidelines (Daley et al. 2020), were fulfilled in 
16 patients (53%), whereas colonization was recognized 
in 14 patients (47%). The pathogenicity of isolated 
M. chimaera strains was not related to sex and age of 
patients (Table  II). NTMLD was observed more fre-
quently among patients with past tuberculosis, bron-
chiectasis, and cystic fibrosis than the remaining ones.
Discussion
M. chimaera has been underdiagnosed in the past 
due to the lack of appropriate methods of identifica-
tion. The growth time of M. chimaera species and its 
morphology are identical to those of M. intracellulare. 
This led to its initial classification in the M. avium com-
plex MAC-A (Tortoli et al. 2004). The identification 
methods used at that time (the Accu Probe and Lipav 1 
tests) did not allow for the identification of M. chimaera 
COPD 7 (44) 1 (7) 8 (27)
Previous tuberculosis 5 (31) 1 (7) 6 (20)
Interstitial lung diseasea 5 (31) 0 5 (17)
Cystic fibrosis 0 2 (14) 2 (7)
Post-inflammatory lung fibrosis 1 (6) 2 (14) 3 (10)
Bronchiectasis 1 (6) 3 (21) 4 (13)
Neoplastic diseaseb 2 (13) 0 2 (7)
Diabetes mellitus 1 (6) 1 (7) 2 (7)
Othersc 0 4 (21) 4 (13)
At least 2 diagnoses 5 (31) 2 (14) 7 (23)
No concomitant disease  1 (6) 1 (7) 2 (7)
Table I
Clinical characteristics of patients with positive M. chimaera isolates.
a – idiopathic pulmonary fibrosis (2 pts), sarcoidosis (2), proteinosis (1)
b – mielofibrosis, lung cancer 
c – bronchial asthma (1), hypothyreosis (1), mediastinal cyst (1), rheumatoid arthritis (1) 
Concomitant diseases
Number (%) of patients
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within MAC species. Based on the 16S rRNA gene anal-
ysis, the species has been classified as M. intracellulare 
(Bills et al. 2009). The ITS region (16S-23S rRNA) anal-
ysis, introduced in 2004, enabled the identification of 
M. chimaera with great confidence (Tortoli et al. 2004; 
Turenne et al. 2007).
In the present study, the analysis of the 23S rRNA 
gene polymorphism with the GenoType NTM-DR test 
enabled to identify M. chimaera in 44% of strains recog-
nized previously with the GenoType CM as M. intracel­
lulare. Schweickert et al. (2008), analyzed 166 clinical 
isolates of M. intracellulare; however, after their sequenc-
ing, 143 strains (86%) were re-classified to M. chimaera.
Wallace et al. (2013) investigated water samples 
obtained from the households of patients suffering 
from NTM infections caused by MAC. Genotyping of 
M. intracellulare strains isolated from the water samples 
showed that 73% of them were M. chimaera. However, 
the analysis of strains isolated from clinical specimens 
of patients resulted in recognition of M. chimaera in 
only four out of 54 patients (Wallace et al. 2013).
In the group of patients studied in this work, M. chi­
maera has been isolated most frequently from the 
patients diagnosed with COPD, past pulmonary tuber-
culosis, and fibrotic interstitial lung diseases. NTMLD 
has been recognized in 53% of patients, mostly in those 
with a history of past tuberculosis, with bronchiectasis, 
or cystic fibrosis.
Analyses carried out in the United States (Boyle 
et al. 2015) and Germany (Schweickert et al. 2008) sug-
gested that M. chimaera was less pathogenic than other 
MAC species, such as M. intracellulare and M. avium. 
Schweickert et al. (2008) identified 143 strains of 
M. chi ma era, but only three isolates were from patients 
(3.3%) with NTMLD. Boyle et al. (2015), reported 43% 
of cases diagnosed with NTMLD among 126 patients 
with M. chimaera isolates. The same authors reported 
NTMLD in 61% to 70% of patients infected with 
M. avium or M. intracellulare (Schweickert et al. 2008; 
Boyle et al. 2015).
In the present study, the most interesting observa-
tion concerned M. chimaera infections that developed 
in patients with past tuberculosis, especially in the male 
population. A similar observation was made by Moon 
et al. (2016), who found past lung tuberculosis in 64% 
of patients with M. chimaera infection. The other NTM 
type often responsible for NTMLD in patients with 
post-tuberculous lung lesions is Mycobacterium kansasii 
(Augustynowicz-Kopeć et al. 2019). It is not known 
whether the higher incidence of NTMLD in those 
NTM-infected patients, who had a history of past tuber-
culosis, is related to the favorable conditions for their 
colonization in the altered lung parenchyma, or a defect 
in the intracellular killing of NTM in these patients.
In our study group, M. chimaera infections were 
diagnosed in all the patients with previously recognized 
Sex
Men 8 (50) 8 (50) 16 (100)
Women  8 (57) 6(43) 14 (100) 0,86
Age
Years (mean+/–SD) 58,3 (16,77) 62,1 (12,86) 60,1 (15,19) 0,72
Diagnosis
Previous tuberculosis 5 (83) 1 (17) 6 (100)
COPD 3 (38) 5 (62) 8 (100)
Cystic fibrosis 2 (100) 0 2 (100)
Interstitial lung diseasesa 2 (40) 3 (60) 5 (100)
Post-inflammatory lung fibrosis 0 3 (100) 3 (100)
Bronchiectasis 4 (100) 0 4 (100)
Neoplastic diseasesb 1 (50) 1 (50) 2 (100)
Diabetes mellitus 1 (50) 1 (50) 2 (100)
Othersc 0 4 (100) 4 (100)
No concomitant disease 2 (100) 0 2 (100)
Table II
Pathogenicity of isolated M. chimaera strains depending on sex, age,
and concomitant pulmonary disease.
a – idiopathic pulmonary fibrosis (2 pts), sarcoidosis (2), proteinosis (1)
b – mielofibrosis, lung cancer
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bronchiectasis. This predisposition is difficult to 
comment on because bronchiectasis may be an early 
radiologic sign of NTMLD or one of the lung diseases 
predisposing to NTMLD. An analysis of the radio-
logical appearance of NTMLD, performed by our 
group in COPD patients, revealed that 50% of patients 
with bronchiectasis were diagnosed with NTMLD, and 
the remaining had NTM colonization confirmed 
(Szturmowicz et al. 2020).
Another disease predisposing to the development of 
NTMLD is cystic fibrosis (Adjemian et al. 2018; Gard-
ner et al. 2019). In our study, two patients with cystic 
fibrosis developed pulmonary infection with M. chi­
maera as an etiological factor. Larcher et al. (2019) 
described patients with cystic fibrosis, in whom recog-
nition and treatment of NTMLD due to M. chimaera 
resulted in the improvement of general condition and 
lung function.
Conclusions
Almost half of M. intracellulare isolates, have 
been reclassified due to implementing the molecular 
GenoType NTM-DR test to M. chimaera, in the pre-
sent study. M. chimaera isolation concerned patients 
diagnosed with COPD, past tuberculosis, and various 
fibrotic interstitial lung diseases. Analysis of clinical 
data documented NTMLD in 53% of patients infected 
with M. chimaera. Patients diagnosed with past tuber-
culosis and with cystic fibrosis, may be a risk group for 
M. chimaera NTMLD, nevertheless, this observation 
must be confirmed in a larger population.
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